pharma · Ulcerative Colitis · Diabetes Mellitus, Type 2
Eli Lilly and
Eli Lilly and Company
Eli Lilly and is a pharma organization headquartered in GURGAON, CN. Primary therapeutic focus areas include Ulcerative Colitis, Diabetes Mellitus, Type 2, Breast Neoplasms, Non Small Cell Lung Cancer, Systemic Lupus Ery
Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
55,860 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Employees
- 55,860
- Programs
- 62
- Drugs
- 42
- Patents
- 0
Orforglipron
Phase 3 · small molecule · Type 2 Diabetes
Orforglipron for Type 2 Diabetes is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Internal code 18566
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Type 2 Diabetes
- Status
- completed
- Trials
- 1